ML achieves Federal Circuit victory for client Merck

September 29, 2022

In a victory for our client Merck, the Federal Circuit affirmed the PTAB’s judgment rejecting a competitor’s challenges, on grounds of anticipation and obviousness, to a Merck patent relating to the treatment of Type-2 diabetes.  Read our client’s response brief and the opinion

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.